161 related articles for article (PubMed ID: 38490077)
1. Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential.
Li D; Wang J; Tuo Z; Yoo KH; Yu Q; Miyamoto A; Zhang C; Ye X; Wei W; Wu R; Feng D
Phytomedicine; 2024 May; 127():155503. PubMed ID: 38490077
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
3. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
[TBL] [Abstract][Full Text] [Related]
4. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway.
Huang Z; Zhong Z; Zhang L; Wang X; Xu R; Zhu L; Wang Z; Hu S; Zhao X
Sci Rep; 2015 Aug; 5():12807. PubMed ID: 26239046
[TBL] [Abstract][Full Text] [Related]
6. Targeting different phenotypes of macrophages: A potential strategy for natural products to treat inflammatory bone and joint diseases.
Gao Y; Xu X; Zhang X
Phytomedicine; 2023 Sep; 118():154952. PubMed ID: 37506402
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic targets in bladder cancer.
Carneiro BA; Meeks JJ; Kuzel TM; Scaranti M; Abdulkadir SA; Giles FJ
Cancer Treat Rev; 2015 Feb; 41(2):170-8. PubMed ID: 25498841
[TBL] [Abstract][Full Text] [Related]
8. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C-α (PKCα) modulates cell apoptosis by stimulating nuclear translocation of NF-kappa-B p65 in urothelial cell carcinoma of the bladder.
Zheng J; Kong C; Yang X; Cui X; Lin X; Zhang Z
BMC Cancer; 2017 Jun; 17(1):432. PubMed ID: 28629334
[TBL] [Abstract][Full Text] [Related]
10. Understanding urothelial carcinoma through cancer pathways.
Schulz WA
Int J Cancer; 2006 Oct; 119(7):1513-8. PubMed ID: 16557569
[TBL] [Abstract][Full Text] [Related]
11. The pivotal role of JAK/STAT and IRS/PI3K signaling pathways in neurodegenerative diseases: Mechanistic approaches to polyphenols and alkaloids.
Kooshki L; Zarneshan SN; Fakhri S; Moradi SZ; Echeverria J
Phytomedicine; 2023 Apr; 112():154686. PubMed ID: 36804755
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.
Brait M; Munari E; LeBron C; Noordhuis MG; Begum S; Michailidi C; Gonzalez-Roibon N; Maldonado L; Sen T; Guerrero-Preston R; Cope L; Parrella P; Fazio VM; Ha PK; Netto GJ; Sidransky D; Hoque MO
Cell Cycle; 2013 Apr; 12(7):1058-70. PubMed ID: 23435205
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
15. Natural products targeting signaling pathways associated with regulated cell death in gastric cancer: Recent advances and perspectives.
Hu Q; Li Z; Li Y; Deng X; Chen Y; Ma X; Zeng J; Zhao Y
Phytother Res; 2023 Jun; 37(6):2661-2692. PubMed ID: 37157181
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
[TBL] [Abstract][Full Text] [Related]
18. Wnt5a / planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker.
Saling M; Duckett JK; Ackers I; Coschigano K; Jenkinson S; Malgor R
Oncotarget; 2017 May; 8(19):31655-31665. PubMed ID: 28427201
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy.
Dasari S; Njiki S; Mbemi A; Yedjou CG; Tchounwou PB
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163459
[TBL] [Abstract][Full Text] [Related]
20. Targeting lactate metabolism and glycolytic pathways in the tumor microenvironment by natural products: A promising strategy in combating cancer.
Kooshki L; Mahdavi P; Fakhri S; Akkol EK; Khan H
Biofactors; 2022 Mar; 48(2):359-383. PubMed ID: 34724274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
